We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Determines Reduced and Oxidized Glutathione

By LabMedica International staff writers
Posted on 31 Jul 2013
Print article
Image: API 3000 triple-quadrupole mass spectrometer (Photo courtesy of Applied Biosystems).
Image: API 3000 triple-quadrupole mass spectrometer (Photo courtesy of Applied Biosystems).
Diminished levels of glutathione (γ-glutamylcysteinylglycine, GSH) and the ratio of GSH to glutathione disulfide (GSSG) can serve as important indicators of oxidative stress and disease risk.

A simple and sensitive liquid chromatography-tandem mass spectrometry (LC–MS/MS) method for measuring whole blood GSH and GSSG has been developed and can easily be implemented in clinical laboratories.

Scientists at Stanford University School of Medicine (CA, USA) developed an approach that minimizes preanalytical variability through a one-step procedure of deproteinization and derivatization that prevents artifactual oxidation of GSH, and is easily adapted to the clinical setting without requiring excessive constraints on sample handling or storage. The team used anonymous, residual blood samples from 59 healthy individuals, 31 males, and 28 females, with an age range 1 to 87 years, with a mean of 25 years.

Compounds were separated by liquid chromatography using a Hypercarb column (Thermo Scientific; Waltham, MA, USA) at room temperature. The GSH and GSSG ions and fragments were detected using the API 3000 triple-quadrupole mass spectrometer (Perkin-Elmer; Waltham, MA, USA). The final concentrations of GSH and GSSG were expressed in units of μmol/L of whole blood.

The lower limits of detection (LLOD) were 0.4 μM for GSH and 0.1 μM for GSSG and the lower limits of quantitation (LLOQ) were 1.5 μM for GSH and 0.1 μM for GSSG. There was excellent linearity for both GSH and GSSG over the ranges of physiologic normal, with inter- and intra-assay coefficient of variation of 3.1% to 4.3% and accuracy between 95% and 101%. Derivatized samples are stable for at least three years when stored at -80 °C and underivatized samples for at least 24 hours at either 4 °C or room temperature. As a group, the mean concentration ± standard deviation for GSH was 900 ± 140 μM, GSSG 1.17 ± 0.43 μM, and GSH/GSSG ratio was 880 ± 370.

The authors concluded that their LC–MS/MS method minimizes preanalytic variability through a one-step procedure of deproteinization and derivatization, and chromatographic conditions that eliminate ion suppression and increase precision and sensitivity. Additional advantages included the small sample requirement, simple and rapid preanalytical processing, and wide automation possibilities, which makes this method ideal for routine and large-scale clinical testing. The study was published on June 15, 2013, in the Journal of Chromatography B.

Related Links:

Stanford University School of Medicine
Thermo Scientific
Perkin-Elmer


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.